Adenosine-to-inosine RNA editing in neurological development and disease

References

• Flamand MN, Meyer KD. The epitranscriptome and synaptic plasticity. Curr Opin Neurobiol. 2019;59:41–48.
   PubMed Web of Science ®Google Scholar
• Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol. 2016;17(2):83–96.
   PubMed Web of Science ®Google Scholar
• Kim U, Wang Y, Sanford T, et al. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A. 1994;91(24):11457–11461
   PubMed Web of Science ®Google Scholar
• Melcher T, Maas S, Herb A, et al. A mammalian RNA editing enzyme. Nature. 1996;379(6564):460–464.
   PubMed Web of Science ®Google Scholar
• Chen CX, Cho DS, Wang Q, et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. Rna. 2000;6(5):755–767
   PubMed Web of Science ®Google Scholar
• Stefl R, Xu M, Skrisovska L, et al. Structure and specific RNA binding of ADAR2 double-stranded RNA binding motifs. Structure. 2006;14(2):345–355.
   PubMed Web of Science ®Google Scholar
• Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995;15(10):5376–5388.
   PubMed Web of Science ®Google Scholar
• Pestal K, Funk C, Snyder JM, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;43(5):933–944
   PubMed Web of Science ®Google Scholar
• Walkley CR, Li JB. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. Genome Biol. 2017;18(1):205.
   PubMedGoogle Scholar
• Wang Y, Chung DH, Monteleone LR, et al. RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells. Nucleic Acids Res. 2019;47(20):10801–10814.
   PubMed Web of Science ®Google Scholar
• Mladenova D, Barry G, Konen LM, et al. Adar3 is involved in learning and memory in Mice. Front Neurosci. 2018;12:243.
   PubMed Web of Science ®Google Scholar
• Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem. 2004;279(6):4952–4961.
   PubMed Web of Science ®Google Scholar
• Higuchi M, Maas S, Single FN, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78–81.
   PubMed Web of Science ®Google Scholar
• Hood JL, Emeson RB. Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr Top Microbiol Immunol. 2012;353:61–90.
   PubMed Web of Science ®Google Scholar
• Pinto Y, Cohen HY, Levanon EY. Mammalian conserved ADAR targets comprise only a small fragment of the human editosome. Genome Biol. 2014;15(1):R5.
   PubMed Web of Science ®Google Scholar
• Lev-Maor G, Sorek R, Levanon EY, et al. RNA-editing-mediated exon evolution. Genome Biol. 2007;8(2):R29.
   PubMed Web of Science ®Google Scholar
• Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature. 1999;399(6731):75–80.
   PubMed Web of Science ®Google Scholar
• Borchert GM, Gilmore BL, Spengler RM, et al. Adenosine deamination in human transcripts generates novel microRNA binding sites. Hum Mol Genet. 2009;18(24):4801–4807.
   PubMed Web of Science ®Google Scholar
• Nakano M, Fukami T, Gotoh S, et al. A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer. J Biol Chem. 2017;292(12):4873–4884.
   PubMed Web of Science ®Google Scholar
• Stellos K, Gatsiou A, Stamatelopoulos K, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22(10):1140–1150.
   PubMed Web of Science ®Google Scholar
• Ramaswami G, Zhang R, Piskol R, et al. Identifying RNA editing sites using RNA sequencing data alone. Nat Methods. 2013;10(2):128–132.
   PubMed Web of Science ®Google Scholar
• Bazak L, Haviv A, Barak M, et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014;24(3):365–376.
   PubMed Web of Science ®Google Scholar
• Neeman Y, Levanon EY, Jantsch MF, et al. RNA editing level in the mouse is determined by the genomic repeat repertoire. RNA. 2006;12(10):1802–1809.
   PubMed Web of Science ®Google Scholar
• Danecek P, Nellåker C, McIntyre RE, et al. High levels of RNA-editing site conservation amongst 15 laboratory mouse strains. Genome Biol. 2012;13(4):26
   PubMed Web of Science ®Google Scholar
• Sakurai M, Ueda H, Yano T, et al. A biochemical landscape of A-to-I RNA editing in the human brain transcriptome. Genome Res. 2014;24(3):522–534.
   PubMed Web of Science ®Google Scholar
• Bahn JH, Lee JH, Li G, et al. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012;22(1):142–150
   PubMed Web of Science ®Google Scholar
• Ivanov A, Memczak S, Wyler E, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10(2):170–177
   PubMed Web of Science ®Google Scholar
• Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34.
   PubMed Web of Science ®Google Scholar
• Dingledine R, Borges K, Bowie D, et al. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7–61
   PubMed Web of Science ®Google Scholar
• Brusa R, Zimmermann F, Koh DS, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science. 1995;270(5242):1677–1680
   PubMed Web of Science ®Google Scholar
• van den Bos MAJ, Geevasinga N, Higashihara M, et al. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20(11):2818
   Web of Science ®Google Scholar
• Takuma H, Kwak S, Yoshizawa T, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46(6):806–815.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427(6977):801.
   PubMed Web of Science ®Google Scholar
• Hideyama T, Yamashita T, Aizawa H, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45(3):1121–1128.
   PubMed Web of Science ®Google Scholar
• Hideyama T, Yamashita T, Suzuki T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30(36):11917–11925.
   PubMed Web of Science ®Google Scholar
• Aizawa H, Sawada J, Hideyama T, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120(1):75–84.
   PubMed Web of Science ®Google Scholar
• Yamashita T, Hideyama T, Hachiga K, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3(1):1307.
   PubMedGoogle Scholar
• Yamashita T, Aizawa H, Teramoto S, et al. Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Sci Rep. 2017;7(1):39994.
   PubMedGoogle Scholar
• Akamatsu M, Yamashita T, Hirose N, et al. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6(1):28649.
   PubMedGoogle Scholar
• Yamashita T, Chai HL, Teramoto S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med. 2013;5(11):1710–1719.
   PubMed Web of Science ®Google Scholar
• Catarzi D, Colotta V, Varano F. Competitive AMPA receptor antagonists. Med Res Rev. 2007;27(2):239–278.
   PubMed Web of Science ®Google Scholar
• Feldmeyer D, Kask K, Brusa R, et al. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat Neurosci. 1999;2(1):57–64.
   PubMed Web of Science ®Google Scholar
• Krestel HE, Shimshek DR, Jensen V, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24(46):10568–10578.
   PubMed Web of Science ®Google Scholar
• Jia Z, Agopyan N, Miu P, et al. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron. 1996;17(5):945–956
   PubMed Web of Science ®Google Scholar
• Kitaura H, Sonoda M, Teramoto S, et al. Ca(2+) -permeable AMPA receptors associated with epileptogenesis of hypothalamic hamartoma. Epilepsia. 2017;58(4):p. e59-e63.
   PubMed Web of Science ®Google Scholar
• Kortenbruck G, Berger E, Speckmann EJ, et al. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol Dis. 2001;8(3):459–468
   PubMed Web of Science ®Google Scholar
• Krestel H, Raffel S, von Lehe M, et al. Differences between RNA and DNA due to RNA editing in temporal lobe epilepsy. Neurobiol Dis. 2013;56:66–73
   PubMed Web of Science ®Google Scholar
• Tan TY, Sedmík J, Fitzgerald MP, et al. Bi-allelic ADARB1 variants associated with microcephaly, intellectual disability, and seizures. Am J Hum Genet. 2020;106(4):467–483
   PubMed Web of Science ®Google Scholar
• Maroofian R, Sedmík J, Mazaheri N, et al. Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine deaminase, cause a severe developmental and epileptic encephalopathy. J Med Genet. 2020. DOI:10.1136/jmedgenet-2020-107048
   Web of Science ®Google Scholar
• Salpietro V, Dixon CL, Guo H, et al. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019;10(1):3094
   PubMedGoogle Scholar
• Galeano F, Tomaselli S, Locatelli F, et al. A-to-I RNA editing: the “ADAR” side of human cancer. Semin Cell Dev Biol. 2012;23(3):244–250.
   PubMed Web of Science ®Google Scholar
• Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5(3):198–206.
   PubMedGoogle Scholar
• Maas S, Patt S, Schrey M, et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98(25):14687–14692
   PubMed Web of Science ®Google Scholar
• Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med. 2002;8(9):971–978.
   PubMed Web of Science ®Google Scholar
• Ishiuchi S, Yoshida Y, Sugawara K, et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci. 2007;27(30):7987–8001
   PubMed Web of Science ®Google Scholar
• Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol. 2004;488(1–3):1–9.
   PubMed Web of Science ®Google Scholar
• Burns CM, Chu H, Rueter SM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387(6630):303–308.
   PubMed Web of Science ®Google Scholar
• Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5(11):105.
   PubMedGoogle Scholar
• Niswender CM, Copeland SC, Herrick-Davis K, et al. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem. 1999;274(14):9472–9478.
   PubMed Web of Science ®Google Scholar
• Abbas AI, Urban DJ, Jensen NH, et al. Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method. Nucleic Acids Res. 2010;38(10):e118.
   PubMed Web of Science ®Google Scholar
• Price RD, Weiner DM, Chang MS, et al. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem. 2001;276(48):44663–44668
   PubMed Web of Science ®Google Scholar
• Marion S, Weiner DM, Caron MG. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem. 2004;279(4):2945–2954.
   PubMed Web of Science ®Google Scholar
• Wahlstedt H, Daniel C, Enstero M, et al. Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009;19(6):978–986.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Grimberg A, Teegarden S, et al. Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci. 2008;28(48):12834–12844.
   PubMed Web of Science ®Google Scholar
• Chagraoui A, Thibaut F, Skiba M, et al. 5-HT2C receptors in psychiatric disorders: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;66:120–135.
   PubMed Web of Science ®Google Scholar
• Jenck F, Bös M, Wichmann J, et al. The role of 5-HT2C receptors in affective disorders. Expert Opin Investig Drugs. 1998;7(10):1587–1599.
   PubMedGoogle Scholar
• Gurevich I, Tamir H, Arango V, et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 2002;34(3):349–356.
   PubMed Web of Science ®Google Scholar
• Niswender CM, Herrick-Davis K, Dilley GE, et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology. 2001;24(5):478–491.
   PubMed Web of Science ®Google Scholar
• Dracheva S, Patel N, Woo DA, et al. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry. 2008;13(11):1001–1010
   PubMed Web of Science ®Google Scholar
• Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett. 2003;346(3):169–172.
   PubMed Web of Science ®Google Scholar
• Weissmann D, van der Laan S, Underwood MD, et al. Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl Psychiatry. 2016;6(8):e878.
   PubMedGoogle Scholar
• Pongs O. Voltage-gated potassium channels: from hyperexcitability to excitement. FEBS Lett. 1999;452(1–2):31–35.
   PubMed Web of Science ®Google Scholar
• Kamb A, Iverson LE, Tanouye MA. Molecular characterization of Shaker, a Drosophila gene that encodes a potassium channel. Cell. 1987;50(3):405–413.
   PubMed Web of Science ®Google Scholar
• Gutman GA, Chandy KG, Grissmer S, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005;57(4):473–508.
   PubMed Web of Science ®Google Scholar
• Bhalla T, Rosenthal JJ, Holmgren M, et al. Control of human potassium channel inactivation by editing of a small mRNA hairpin. Nat Struct Mol Biol. 2004;11(10):950–956
   PubMed Web of Science ®Google Scholar
• Decher N, Streit AK, Rapedius M, et al. RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. Embo J. 2010;29(13):2101–2113.
   PubMed Web of Science ®Google Scholar
• Streit AK, Derst C, Wegner S, et al. RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats. Epilepsia. 2011;52(3):645–648.
   PubMed Web of Science ®Google Scholar
• Graves TD, Cha Y-H, Hahn AF, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014;137(Pt 4):1009–1018.
   PubMedGoogle Scholar
• Imbrici P, D’Adamo MC, Kullmann DM, et al. Episodicataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kvβ1.1 and Kv1.4-1.1/Kvβ1.2. Eur J Neurosci. 2006;24(11):3073–3083.
   PubMed Web of Science ®Google Scholar
• Tomlinson SE, Rajakulendran S, Tan SV, et al. Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1. J Neurol Neurosurg Psychiatry. 2013;84(10):1107–1112.
   PubMed Web of Science ®Google Scholar
• Ferrick-Kiddie EA, Rosenthal JJC, Ayers GD, et al. Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing. Sci Rep. 2017;7(1):41095.
   PubMedGoogle Scholar
• Wu B, Hur S. How RIG-I like receptors activate MAVS. Curr Opin Virol. 2015;12:91–98.
   PubMed Web of Science ®Google Scholar
• Liddicoat BJ, Piskol R, Chalk AM, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science. 2015;349(6252):1115–1120.
   PubMed Web of Science ®Google Scholar
• Mannion NM, Greenwood SM, Young R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014;9(4):1482–1494.
   PubMed Web of Science ®Google Scholar
• Orcesi S, La Piana R, Fazzi E. Aicardi-Goutieres syndrome. Br Med Bull. 2009;89:183–201.
   PubMed Web of Science ®Google Scholar
• Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15(7):429–440.
   PubMed Web of Science ®Google Scholar
• Rice GI, Forte GMA, Mannion NM, et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat Genet. 2012;44(11):1243–1248.
   PubMed Web of Science ®Google Scholar
• Schmelzer L, Smitka M, Wolf C, et al. Variable clinical phenotype in two siblings with Aicardi-Goutières syndrome type 6 and a novel mutation in the ADAR gene. Eur J Paediatr Neurol. 2018;22(1):186–189.
   PubMed Web of Science ®Google Scholar
• Ahmad S, Mu X, Yang F, et al. Breaching self-tolerance to Alu Duplex RNA underlies MDA5-mediated inflammation. Cell. 2018;172(4):797–810. e13.
   PubMed Web of Science ®Google Scholar
• Kono M, Akiyama M. Dyschromatosis symmetrica hereditaria and reticulate acropigmentation of Kitamura: an update. J Dermatol Sci. 2019;93(2):75–81.
   PubMed Web of Science ®Google Scholar
• Kondo T, Suzuki T, Ito S, et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J Dermatol. 2008;35(10):662–666
   PubMed Web of Science ®Google Scholar
• Suzuki N, Suzuki T, Inagaki K, et al. Ten novel mutations of the ADAR1 gene in Japanese patients with dyschromatosis symmetrica hereditaria. J Invest Dermatol. 2007;127(2):309–311.
   PubMed Web of Science ®Google Scholar
• Livingston JH, Lin JP, Dale RC, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51(2):76–82
   PubMed Web of Science ®Google Scholar
• Crow YJ, Zaki M, Abdel-Hamid M, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics. 2014;45(6):386–393.
   PubMed Web of Science ®Google Scholar
• Samuel CE. ADARs: viruses and innate immunity. Curr Top Microbiol Immunol. 2012;353:163–195.
   PubMed Web of Science ®Google Scholar
• Gélinas JF, Clerzius G, Shaw E, et al. Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. J Virol. 2011;85(17):8460–8466
   Google Scholar
• Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006;4(12):900–908.
   PubMed Web of Science ®Google Scholar
• Oldstone MB. Modeling subacute sclerosing panencephalitis in a transgenic mouse system: uncoding pathogenesis of disease and illuminating components of immune control. Curr Top Microbiol Immunol. 2009;330:31–54.
   PubMed Web of Science ®Google Scholar
• Bass BL, Weintraub H, Cattaneo R, et al. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell. 1989;56(3):331.
   PubMed Web of Science ®Google Scholar
• Ward SV, George CX, Welch MJ, et al. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc Natl Acad Sci U S A. 2011;108(1):331–336.
   PubMed Web of Science ®Google Scholar
• Toth AM, Li Z, Cattaneo R, et al. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem. 2009;284(43):29350–29356.
   PubMed Web of Science ®Google Scholar
• Pfaller CK, Mastorakos GM, Matchett WE, et al. Measles virus defective interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA-1-Like hypermutations. J Virol. 2015;89(15):7735–7747.
   PubMed Web of Science ®Google Scholar
• Berghäll H, Sirén J, Sarkar D, et al. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 2006;8(8):2138–2144.
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Schmid A, Eschle D, et al. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55(2):255–265.
   PubMed Web of Science ®Google Scholar
• Lomeli H, Mosbacher J, Melcher T, et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science. 1994;266(5191):1709–1713.
   PubMed Web of Science ®Google Scholar
• Schoft VK, Schopoff S, Jantsch MF. Regulation of glutamate receptor B pre-mRNA splicing by RNA editing. Nucleic Acids Res. 2007;35(11):3723–3732.
   PubMed Web of Science ®Google Scholar
• Venø M, Bramsen JB, Bendixen C, et al. Spatio-temporal regulation of ADAR editing during development in porcine neural tissues. RNA Biol. 2012;9(8):1054–1065.
   PubMed Web of Science ®Google Scholar
• Pachernegg S, Münster Y, Muth-Köhne E, et al. GluA2 is rapidly edited at the Q/R site during neural differentiation in vitro. Front Cell Neurosci. 2015;9:69
   PubMed Web of Science ®Google Scholar
• Barbon A, Barlati S. Glutamate receptor RNA editing in health and disease. Biochemistry (Mosc). 2011;76(8):882–889.
   PubMed Web of Science ®Google Scholar
• Egebjerg J, Heinemann SF. Ca2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci U S A. 1993;90(2):755–759.
   PubMed Web of Science ®Google Scholar
• Kohler M, Burnashev N, Sakmann B, et al. Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron. 1993;10(3):491–500.
   PubMed Web of Science ®Google Scholar
• Paschen W, Schmitt J, Gissel C, et al. Developmental changes of RNA editing of glutamate receptor subunits GluR5 and GluR6: in vivo versus in vitro. Brain Res Dev Brain Res. 1997;98(2):271–280.
   PubMedGoogle Scholar
• Bernard A, Ferhat L, Dessi F, et al. Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation. Eur J Neurosci. 1999;11(2):604–616.
   PubMed Web of Science ®Google Scholar
• Vissel B, Royle GA, Christie BR, et al. The role of RNA editing of kainate receptors in synaptic plasticity and seizures. Neuron. 2001;29(1):217–227.
   PubMed Web of Science ®Google Scholar
• Sailer A, Swanson GT, Pérez-Otaño I, et al. Generation and analysis of GluR5(Q636R) kainate receptor mutant mice. J Neurosci. 1999;19(20):8757–8764.
   PubMed Web of Science ®Google Scholar
• Burnashev N, Zhou Z, Neher E, et al. Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes. J Physiol. 1995;485(Pt 2):403–418.
   PubMed Web of Science ®Google Scholar
• Ortinski PI, Lu C, Takagaki K, et al. Expression of distinct α subunits of GABAA receptor regulates inhibitory synaptic strength. J Neurophysiol. 2004;92(3):1718–1727.
   PubMed Web of Science ®Google Scholar
• Ohlson J, Pedersen JS, Haussler D, et al. Editing modifies the GABA(A) receptor subunit alpha3. Rna. 2007;13(5):698–703.
   PubMed Web of Science ®Google Scholar
• Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci. 1996;16(3):1114–1122.
   PubMed Web of Science ®Google Scholar
• Irimia M, Denuc A, Ferran JL, et al. Evolutionarily conserved A-to-I editing increases protein stability of the alternative splicing factor Nova1. RNA Biol. 2012;9(1):12–21.
   PubMed Web of Science ®Google Scholar
• Striessnig J, Koschak A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels (Austin). 2008;2(4):233–251.
   PubMed Web of Science ®Google Scholar
• Huang H, Tan B, Shen Y, et al. RNA editing of the IQ domain in Cav1.3 channels modulates their Ca2+-dependent inactivation. Neuron. 2012;73(2):304–316.
   PubMed Web of Science ®Google Scholar
• Li JB, Levanon EY, Yoon JK, et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science. 2009;324(5931):1210–1213
   PubMed Web of Science ®Google Scholar
• Miyake K, Ohta T, Nakayama H, et al. CAPS1 RNA editing promotes dense core vesicle exocytosis. Cell Rep. 2016;17(8):2004–2014.
   PubMed Web of Science ®Google Scholar
• Ulbricht R, Sun S, DelBove C, et al. RNA editing of CAPS1 regulates synaptic vesicle organization, release and retrieval. bioRxiv. 2017;178202
   Google Scholar
• Terajima H, Yoshitane H, Ozaki H, et al. ADARB1 catalyzes circadian A-to-I editing and regulates RNA rhythm. Nat Genet. 2017;49(1):146–151.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 2006;13(1):13–21.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Megraw M, Kreider E, et al. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res. 2008;36(16):5270–5280.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Zinshteyn B, Chendrimada TP, et al. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep. 2007;8(8):763–769
   PubMed Web of Science ®Google Scholar
• Iizasa H, Wulff B-E, Alla NR, et al. Editing of epstein-barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem. 2010;285(43):33358–33370.
   PubMed Web of Science ®Google Scholar
• Ekdahl Y, Farahani HS, Behm M, et al. A-to-I editing of microRNAs in the mammalian brain increases during development. Genome Res. 2012;22(8):1477–1487.
   PubMed Web of Science ®Google Scholar
• Paul D, Sinha AN, Ray A, et al. A-to-I editing in human miRNAs is enriched in seed sequence, influenced by sequence contexts and significantly hypoedited in glioblastoma multiforme. Sci Rep. 2017;7(1):2466.
   PubMedGoogle Scholar
• Vesely C, Tauber S, Sedlazeck FJ, et al. ADAR2 induces reproducible changes in sequence and abundance of mature microRNAs in the mouse brain. Nucleic Acids Res. 2014;42(19):12155–12168.
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Zinshteyn B, Sethupathy P, et al. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science. 2007;315(5815):1137.
   PubMed Web of Science ®Google Scholar
• Fiore R, Khudayberdiev S, Christensen M, et al. Mef2-mediated transcription of the miR379–410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. Embo J. 2009;28(6):697–710.
   PubMed Web of Science ®Google Scholar
• Tomaselli S, Galeano F, Alon S, et al. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 2015;16(1):5.
   PubMedGoogle Scholar
• Choudhury Y, Tay FC, Lam DH, et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012;122(11):4059–4076.
   PubMed Web of Science ®Google Scholar
• Quinones-Valdez G, Tran SS, Jun H-I, et al. Regulation of RNA editing by RNA-binding proteins in human cells. Commun Biol. 2019;2(1):19.
   PubMedGoogle Scholar
• Hwang T, Park CK, Leung AK, et al. Dynamic regulation of RNA editing in human brain development and disease. Nat Neurosci. 2016;19(8):1093–1099
   PubMed Web of Science ®Google Scholar
• Chalk AM, Taylor S, Heraud-Farlow JE, et al. The majority of A-to-I RNA editing is not required for mammalian homeostasis. Genome Biol. 2019;20(1):268.
   PubMed Web of Science ®Google Scholar
• Montiel-Gonzalez MF, Diaz Quiroz JF, Rosenthal JJC. Current strategies for site-directed RNA editing using ADARs. Methods. 2019;156:16–24.
   PubMed Web of Science ®Google Scholar
• Picardi E, Horner DS, Pesole G. Single-cell transcriptomics reveals specific RNA editing signatures in the human brain. Rna. 2017;23(6):860–865.
   PubMed Web of Science ®Google Scholar